Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion

被引:4
|
作者
Christopher Valerio [1 ]
Eleni Theocharidou [2 ]
Andrew Davenport [3 ]
Banwari Agarwal [1 ]
机构
[1] Intensive Care Unit, Royal Free Hospital, Royal Free Hampstead NHS Trust, University College London
[2] the Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, Royal Free Hampstead NHS Trust and Institute of Liver and Digestive Health, University College London
[3] UCL Centre for Nephrology, Royal Free Hospital
关键词
Human serum albumin; Human albumin solution; Critical illness; Cirrhosis; Resuscitation fluid; Large-volume paracentesis; Hepatorenal syndrome; Spontaneous bacterial peritonitis;
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
To provide an overview of the properties of human serum albumin(HSA), and to review the evidence for the use of human albumin solution(HAS) in critical illness, sepsis and cirrhosis. A MEDLINE search was performed using the terms "human albumin", "critical illness", "sepsis" and "cirrhosis". The references of retrieved articles were reviewed manually. Studies published between 1980 and 2014 were selected based on quality criteria. Data extraction was performed by all authors. HSA is the main plasma protein contributing greatly to its oncotic pressure. HSA demonstrates important binding properties for endogenous and exogenous toxins, drugs and drug metabolites that account for its anti-oxidant and anti-inflammatory properties. In disease states, hypoalbuminaemia is secondary to decreased HSA production, increased loss or transcapillary leakage into the interstitial space. HSA function can be also altered in disease with reduced albumin binding capacity and increased production of modified isoforms. HAS has been used as volume expander in critical illness, but received criticism due to cost and concerns regarding safety. More recent studies confirmed the safety of HAS, but failed to show any survival benefit compared to the cheaper crystalloid fluids, therefore limiting its use. On the contrary, in cirrhosis there is robust data to support the efficacy of HAS for the prevention of circulatory dysfunction post-large volume paracentesis and in the context of spontaneous bacterial peritonitis, and for the treatment of hepato-renal syndrome and hypervolaemic hyponatraemia. It is likely that not only the oncotic properties of HAS are beneficial in cirrhosis, but also its functional properties, as HAS replaces the dysfunctional HSA. The role of HAS as the resuscitation fluid of choice in critically ill patients with cirrhosis, beyond the established indications for HAS use, should be addressed in future studies.
引用
收藏
页码:345 / 354
页数:10
相关论文
共 50 条
  • [31] Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
    Moreau, Richard
    Jalan, Rajiv
    Gines, Pere
    Pavesi, Marco
    Angeli, Paolo
    Cordoba, Juan
    Durand, Francois
    Gustot, Thierry
    Saliba, Faouzi
    Domenicali, Marco
    Gerbes, Alexander
    Wendon, Julia
    Alessandria, Carlo
    Laleman, Wim
    Zeuzem, Stefan
    Trebicka, Jonel
    Bernardi, Mauro
    Arroyo, Vicente
    GASTROENTEROLOGY, 2013, 144 (07) : 1426 - U189
  • [32] Acute kidney injury (AKI) in patients with Acute on Chronic Liver failure (ACLF) is different from patients with cirrhosis
    Maiwall, Rakhi
    Kumar, Suman
    Vashishtha, Chitranshu
    Kumar, Manoj
    Garg, Hitendra K.
    Nayak, Sumanlata
    Taneja, Sunil
    Thakur, Bhaskar
    Sarin, Shiv K.
    HEPATOLOGY, 2013, 58 : 272A - 272A
  • [33] Single center validation of scores for prediction of mortality in patients with acute-on-chronic liver failure or acute decompensation of cirrhosis without acute-on-chronic liver failure
    Alexopoulou, A.
    Vasilieva, L.
    Mani, I.
    Agiasotelli, D.
    Dourakis, S. P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S124 - S124
  • [34] Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report
    Zhou, Jiuqin
    Chen, Si
    Zhang, Lin
    Zhai, Yongzhen
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (01) : 153 - 157
  • [35] Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report
    Jiuqin Zhou
    Si Chen
    Lin Zhang
    Yongzhen Zhai
    DARU Journal of Pharmaceutical Sciences, 2022, 30 : 153 - 157
  • [36] Mortality Is Underestimated in Cirrhosis Patients with Acute on Chronic Liver Failure According to Physician Survey
    Burke, S.
    Miller, A. C.
    Patolia, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [37] Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
    Yuan, Haixia
    Cao, Yingying
    Yu, Zhenjun
    Huang, Yue
    Liu, Fang
    Gao, Yanying
    Qiu, Shaotian
    Han, Tao
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [38] Long term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis
    Seige, M
    Kreymann, B
    Jeschke, B
    Schweigart, U
    Kopp, KF
    Classen, M
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 1371 - 1375
  • [39] Does the presence of cirrhosis influence on the mortality rate in patients with acute on chronic liver failure?
    Treeprasertsuk, Sombat
    Thanapirom, Kessarin
    Chaiteerakij, Roongruedee
    Choudhary, Ashok
    Sharma, Manoj
    Maiwall, Rakhi
    Pamecha, Viniyendra
    Moreau, Richard
    Mahtab, Mamun A.
    Chawla, Yogesh K.
    Tan, Soek Siam
    Devarbhavi, Harshad
    Chen, Yu
    Duan, Zhongping
    Ning, Qin
    Amarapurkar, Deepak N.
    Hamid, Saeed
    Butt, Amna S.
    Ghazinyan, Hasmik
    Lee, Guan Huei
    Sood, Ajit
    Lesmana, Laurentius A.
    Shiha, Gamal
    Payawal, Diana A.
    Dokmeci, Abdulkadir
    Sarin, Shiv K.
    HEPATOLOGY, 2016, 64 : 1017A - 1018A
  • [40] Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
    Haixia Yuan
    Yingying Cao
    Zhenjun Yu
    Yue Huang
    Fang Liu
    Yanying Gao
    Shaotian Qiu
    Tao Han
    BMC Gastroenterology, 23